Argenica Therapeutics (ASX:AGN) has strengthened the evidence base behind its lead neuroprotective candidate, ARG-007, with new independently generated data confirming a potent therapeutic effect in a validated preclinical model of acute ischaemic stroke. …
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 Australian Biotech
Latest Video
New Stories
-
Guilt over this enduring failure is the correct response
September 9, 2026 - -
Poweroos chase world title in Argentina with new backing from Biogen
September 9, 2026 - - Latest News -
What will AI be capable of in two months? We don't know, and that's the point
September 9, 2026 - - Latest News -
'You can't fix a broken system by tinkering with parts of it'
September 9, 2026 - - Latest News -
A review recommendation that should be reconsidered because of time
September 8, 2026 - - Latest News -
The forgotten patients living in the long shadow of rare cancer
September 8, 2026 - - Latest News -
Pharmacists could save women millions and cut GP queues, new analysis shows
September 8, 2026 - - Latest News